SCHEMBL29575795

SCHEMBL29575795

COc1cc(NS(=O)(=O)c2ccc(C)cc2)c2ncccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 1.00
TDP1 Q9NUW8 6/20 1.00
MEN1 O00255 5/20 1.00
LMNA P02545 2/20 1.00
MAPT P10636 2/20 1.00
AGTR1 P30556 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00
TP53 P04637 1/20 1.00
HPGD P15428 1/20 1.00
TSHR P16473 1/20 1.00
CXCR2 P25025 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
CKS1B P61024 4/20 0.85
SKP2 Q13309 4/20 0.85
SLC40A1 Q9NP59 10/20 0.82
POLB P06746 1/20 0.79
NFKBIA P25963 3/20 0.71
RELA Q04206 2/20 0.71
MITF O75030 1/20 0.67
S1PR4 O95977 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1505430 1.00 KMT2A (1.00) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL13633886 0.93 MEN1 (1.00) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL17506531 0.92 CKS1B (1.00) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL7197593 0.90 SLC40A1 (1.00) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL4489851 0.89 MEN1 (0.84) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL22111633 0.89 MEN1 (0.84) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL17506539 0.88 KMT2A (0.79) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL22076984 0.88 MEN1 (1.00) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL4472564 0.86 MEN1 (0.79) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL6688368 0.86 SLC40A1 (0.85) KMT2ATDP1MEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642997-A1 ZINC-BASED SULFUR COMPOUND SCAVENGER WITH REDUCED SOLIDS DEPOSITION Baker Hughes Oilfield Operations LLC (US) 2025-11-05 EP disclosed
US-12343335-B2 Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function ZINCURE CORP. (KR) 2025-07-01 US disclosed
CN-119505252-A Organometallic framework ultrasound contrast agent for activating tumor immunity and preparation method and application thereof 山东大学齐鲁医院 2025-02-25 CN disclosed
WO-2024145404-A1 ZINC-BASED SULFUR COMPOUND SCAVENGER WITH REDUCED SOLIDS DEPOSITION BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2024-07-04 WO disclosed
US-20240218273-A1 ZINC-BASED SULFUR COMPOUND SCAVENGER WITH REDUCED SOLIDS DEPOSITION BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2024-07-04 US disclosed
WO-2024112438-A1 POLYUNSATURATED FATTY ACID-BOUND ALPHA FETOPROTEIN PROMOTES IMMUNE SUPPRESSION BY ALTERING HUMAN DENDRITIC CELL METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-30 WO disclosed
CN-116710467-A Photooxidation reduction protein modification 罗莎琳德·富兰克林研究所 2023-09-05 CN disclosed
US-11649228-B2 Zinc indicators for cellular imaging THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-05-16 US disclosed
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION ZINCURE CORP. (KR) 2023-01-05 US disclosed
EP-4066832-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION Zincure Corp. (KR) 2022-10-05 EP disclosed
CN-114929217-A Pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis control function 锌医疗公司 2022-08-19 CN disclosed
WO-2022118054-A1 RED FLUORESCENT SENSOR COMPOUNDS FOR THE DETECTION OF METAL IONS FEMTONICS KFT. (HU) 2022-06-09 WO disclosed
CN-109952297-B Compound (I) 奥斯陆大学 2022-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION PRKAB1, PRKAB2, PRKAG1 KMT2A 2170/4885TDP1 4228/4885MEN1 3953/4885
US-11649228-B2 Zinc indicators for cellular imaging IAPP, SLC30A6, SLC30A7 KMT2A 4760/4885TDP1 3228/4885MEN1 2196/4885
US-12343335-B2 Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function PRKAB1, PRKAB2, PRKAG1 KMT2A 2170/4885TDP1 4228/4885MEN1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.